Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-04-09
2011-12-27
Hanley, Susan (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S007600, C514S015400, C514S015500
Reexamination Certificate
active
08084424
ABSTRACT:
Disclosed are methods and compositions related to the production of erythropoietin. The disclosed compositions comprise a poly amino acid. The production of erythropoietin by the disclosed compositions and methods can take place in vivo, in which the proliferation of a subject's erythropoietin-producing cells leads to an increased level of production of erythropoietin, in vitro, in which increased proliferation of cultured erythropoietin-producing cells leads to an increased production of erythropoietin, ex vivo, in which cells or tissues harvested from a subject produce erythropoietin. The disclosed compositions can be administered to a subject or applied to cells or tissues to stimulate increased production of erythropoietin. The disclosed compositions and methods can be used, for example, to treat anemia, such as anemia associated with diseases and disorders such as chronic renal failure, end stage renal disease, malignancies, HIV infections and AIDS, rheumatoid arthritis, myeloma, and myeloplastic syndrome, and other diseases and disorders.
REFERENCES:
patent: 4526888 (1985-07-01), Williams et al.
patent: 4667016 (1987-05-01), Lai et al.
patent: 4703008 (1987-10-01), Lin
patent: 4935350 (1990-06-01), Patel et al.
patent: 4987121 (1991-01-01), Baertschi et al.
patent: 5032507 (1991-07-01), Yu et al.
patent: 5104653 (1992-04-01), Michalevicz
patent: 5106760 (1992-04-01), Egrie
patent: 5354934 (1994-10-01), Pitt et al.
patent: 5476653 (1995-12-01), Pitt et al.
patent: 5482924 (1996-01-01), Royet et al.
patent: 5547933 (1996-08-01), Lin
patent: 5597562 (1997-01-01), Nomura et al.
patent: 5618698 (1997-04-01), Lin
patent: 5621080 (1997-04-01), Lin
patent: 5661125 (1997-08-01), Strickland
patent: 5756349 (1998-05-01), Lin
patent: 5830705 (1998-11-01), Souza
patent: 5885574 (1999-03-01), Elliott
patent: 5919464 (1999-07-01), Mann et al.
patent: 5955422 (1999-09-01), Lin
patent: 6080557 (2000-06-01), Sims et al.
patent: 6221397 (2001-04-01), Russell-Jones et al.
patent: 6319499 (2001-11-01), Elliott
patent: 6784154 (2004-08-01), Westenfelder
patent: 2001/0038859 (2001-11-01), Maskiewicz et al.
patent: 2003/0108556 (2003-06-01), Mekalanos et al.
patent: 2003/0109452 (2003-06-01), Owen
patent: 2003/0219407 (2003-11-01), Ding et al.
patent: 2321898 (1977-03-01), None
patent: WO 0027997 (2000-05-01), None
patent: WO 01/66149 (2001-09-01), None
Sigma Catalog (1998) p. 2105.
Kurtz A, Jelkmann W, Pfeilschifter J, Bauer C. (1986) Erythropoietin Production in Cultures of Rat Renal Mesangial Cells.Contr. Nephrol., 50: 175-87.
Kurtz A, Jelkmann W, Pfuhl A, Malmstrom K, Bauer C. (1986) Erythropoietin Production by Fetal Mouse Liver Cells in Response to Hypoxia and Adenylate Cyclase Stimulation.Endocrinology, 118 (2): 567-72.
Masuda S, Chikuma M, Sasaki R. (1997) Insulin-Like Growth Factors and Insulin Stimulate Erythropoietin Production in Primary Cultured Astrocytes.Brain Res., 746(1-2): 63-70.
Wang MD, Yang M, Huzel N, Butler M. (2002) Erythropoietin Production from CHO Cells Grown by Continuous Culture in a Fluidized-bed Bioreactor.Biotechnology Bioeng., 77(2): 194-203.
Abbate, M., et al., “Proteinuria as a mediator of tubulointerstitial injury,” Kidney Blood Press Res 22:37-46, 1999.
Anagnostou, A., et al., “Factors which affect erythropoiesis in partially nephrectomized and sham-operated rats,” Blood 48:425-433, 1976.
Bachmann, S., et al., “Co-localization of erythropoietin messenger RNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin,” J. Histochem Chytochem 41:335-341, 1993.
Bellizzi, V., et al., The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model, Nephrol Dial. Transplant 13:2210-2215, 1998.
Browne, et al., “Erythropoietin: Gene cloning, protein structure, and biological properties,” Cold Spring Harbor Symposia on Quantitative Biology, L1:693-702, 1986.
Burton, C., et al., “The role of proteinuria in the progression of chronic renal failure,” Am. J. Kidney Dis. 27:765-775, 1996.
Carlini, R., et al., “Recombinant human erythropoietin stimulates angiogenesis in vitro,” Kidney, Int. 47:740-745, 1995.
Dendorfer, U., “Molecular biology of cytokines, Art. Organs,” 20:437-444, 1996.
Donnelly, S., “Why is erythropoietin made in the kidney? The kidney functions as a critmeter,” Am J. Kidney Dis. 38:415-425, 2001.
Eddy, A.A., “Interstitial nephritis induced by protein overlaod proteinuria,” Am. J. Pathol. 135:719-733, 1989.
Eddy, A.A., “Molecular basis of renal fibrosis,” Pediatr. Nephrol. 15:290-301, 2000.
Eddy, A.A., “Role of cellular infiltrates in response to proteinuria,” Am. J. Kidney Dis., 37:S25-S29, 2001.
Ferrara, N., Molecuar and biological properties of vascular endothelial growth factor, J. Mole. Med. 77:527-543, 1999.
Gandi, R., et al., “Immunolocalization of ecto-5′-nucleotidase in the kidney by a monoclonal antibody,” Histochemistry 95:165-174, 1990.
Ghielli, M., et al., “Inflammatory cells in renal pathology,” Néphrologie 19:59-67, 1998.
Gleadle, J.M. et al., “Induction of hypoxia-inducible factor-1 erythropoietin, vascular endothelial growth factor and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase,” Blood 89:503-509, 1997.
Ivan, M., et al., “HIF alpha targeted for VHL-mediated destruction by praline hydroxylation: implications for O2sensing,” Science 292:464-468, 2001.
Jaakkola, P., et al., “Targeting of HIF alpha to the von Hippel-Lindau urbiquitylation complex by O2regulated prolyl hydroxylation,” Science 292:468-472, 2001.
Jelkmann, W., “Erythropoietin: structure, control of production, and function,” Physio. Rev. 72:449-489, 1992.
Johnson, D.W., “Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-1 axis,” Kidney Int. 52:1486-1496, 1997.
Kaissling, B., Morphology of interstitial cells in the healthy kidney, Anat. Embryol. 193:303-318, 1996.
Keane, W.F., Proteinuria: its clinical importance and role in progressive renal disease, AM. J. Kidney Dis. 35:S97-S105, 2000.
Kendall, R.G., “Erythropoietin,” Clin. Lab. Hematol. 23:71-80, 2001.
Kishore, B.K., “Mechanism of the thesaurismosis and altered lysosomal dynamics induced by poly-D-glutamic acid in kidney proximal tubular cells,” Lab. Invest. 74:1025-1037, 1996.
Kishore, B.K., et al., “Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria,” Kidney Int. 58:701-711, 2000.
Kishore, B.K., et al., “Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids,” J. Pharmacol. Exp. Ther. 255:875-885, 1990.
Kishore, B.K., et al., “Poly-D-glutamic acid induces an acute lysosomal thesaurismosis of proximal tubules and a marked proliferation of interstitium in rat kidney,” Lab. Invest. 74:1013-1023, 1996.
Koury, S., et al., “Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization,” Blood 71:524-527, 1988.
Koury, S., et al., “Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization. Correlation with hamtocrit, renal erythropoietin mRNA and serum erythropoietin concentration,” Blood 74:645-651, 1989.
Krantz, S., “Erythropoietin,” Blood 77:419-434, 1991.
Lacombe, C., et al., The molecular biology of erythropoietin, Nephrol. Dial. Transplant 14:22-28, 1999.
Lando, D.F., et al., “Aspargine hydroxylation of HIF alpha transactivation domain: a hypoxic switch,” Science 295:858-861, 2002.
Le Hir, et al., “Distribution of 5′-nuclleotides in the renal interstitium of the rat,” Cel
Issac Jorge
Kishore Bellamkonda
Westenfelder Christof
Ballard Spahr LLP
Hanley Susan
University of Utah Research Foundation
LandOfFree
Compositions and methods related to erythropoietin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods related to erythropoietin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods related to erythropoietin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261621